In last trading session, Can-Fite Biopharma Ltd ADR (AMEX:CANF) saw 0.37 million shares changing hands with its beta currently measuring 1.16. Company’s recent per share price level of $1.81 trading at -$0.1 or -5.24% at ring of the bell on the day assigns it a market valuation of $18.24M. That closing price of CANF’s stock is at a discount of -159.12% from its 52-week high price of $4.69 and is indicating a premium of 28.73% from its 52-week low price of $1.29.

For Can-Fite Biopharma Ltd ADR (CANF), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Can-Fite Biopharma Ltd ADR (AMEX:CANF) trade information

Upright in the red during last session for losing -5.24%, in the last five days CANF remained trading in the green while hitting it’s week-highest on Friday, 02/21/25 when the stock touched $1.81 price level, adding 11.27% to its value on the day. Can-Fite Biopharma Ltd ADR’s shares saw a change of 11.38% in year-to-date performance and have moved 19.87% in past 5-day. Can-Fite Biopharma Ltd ADR (AMEX:CANF) showed a performance of 17.53% in past 30-days.

Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 81.9% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -452.49% in reaching the projected high whereas dropping to the targeted low would mean a loss of -452.49% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 48.75% during past 5 years.